Targeting Histone Lysine Demethylase KDM4A in Neuroendocrine Prostate Cancer
Abstract
Neuroendocrine prostate cancer represents a highly lethal subtype of castration resistant prostate cancer (CRPC) that lacks effective treatment options. Despite the low incidence of de novo NEPC, the incidence of treatment-related NEPC (t-NEPC) is on the rise, which emerges in prostate adenocarcinoma treated with potent androgen receptor pathway inhibitors as a mechanism of therapeutic resistance. We identified histone lysine demethylase KDM4A as a epigenetic regulator that is highly expressed in NEPC. Our research focuses on the role of 4A in tumor progression of neuroendocrine prostate cancer (NEPC), the mechanisms by which KDM4A drives NEPC progression, and the efficacy of KDM4 inhibitor as monotherapy and combination therapy in NEPC.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2022
- Accession Number
- AD1190929
Entities
People
- Guocan Wang
Organizations
- The University of Texas MD Anderson Cancer Center